View in EDS HTML Full Text PDF Full Text

Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.

Saved in:
Bibliographic Details
Title: Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
Authors: Cork MJ; Sheffield Dermatology Research, Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK.; Sheffield Children's Hospital Clinical Research Facility, Sheffield, UK., Thaçi D; Institute and Comprehensive Center of Inflammation Medicine, University of Lübeck, Lübeck, Germany., Eichenfield LF; Departments of Dermatology, University of California San Diego School of Medicine, San Diego, CA, USA., Arkwright PD; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK., Sun X; Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA., Chen Z; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Akinlade B; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Boklage S; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Guillemin I; Sanofi, Chilly Mazarin, France., Kosloski MP; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Kamal MA; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., O'Malley JT; Sanofi, Cambridge, MA, USA., Patel N; Sanofi, Cambridge, MA, USA., Graham NMH; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Bansal A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Source: The British journal of dermatology [Br J Dermatol] 2021 May; Vol. 184 (5), pp. 857-870. Date of Electronic Publication: 2020 Oct 09.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32969489
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to &amp;lt; 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Cork+MJ%22&quot;&gt;Cork MJ&lt;/searchLink&gt;; Sheffield Dermatology Research, Department of Infection, Immunity &amp; Cardiovascular Disease, University of Sheffield, Sheffield, UK.; Sheffield Children&#39;s Hospital Clinical Research Facility, Sheffield, UK.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Tha&#231;i+D%22&quot;&gt;Tha&#231;i D&lt;/searchLink&gt;; Institute and Comprehensive Center of Inflammation Medicine, University of L&#252;beck, L&#252;beck, Germany.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Eichenfield+LF%22&quot;&gt;Eichenfield LF&lt;/searchLink&gt;; Departments of Dermatology, University of California San Diego School of Medicine, San Diego, CA, USA.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Arkwright+PD%22&quot;&gt;Arkwright PD&lt;/searchLink&gt;; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Sun+X%22&quot;&gt;Sun X&lt;/searchLink&gt;; Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Chen+Z%22&quot;&gt;Chen Z&lt;/searchLink&gt;; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Akinlade+B%22&quot;&gt;Akinlade B&lt;/searchLink&gt;; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Boklage+S%22&quot;&gt;Boklage S&lt;/searchLink&gt;; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Guillemin+I%22&quot;&gt;Guillemin I&lt;/searchLink&gt;; Sanofi, Chilly Mazarin, France.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Kosloski+MP%22&quot;&gt;Kosloski MP&lt;/searchLink&gt;; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Kamal+MA%22&quot;&gt;Kamal MA&lt;/searchLink&gt;; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22O&#39;Malley+JT%22&quot;&gt;O&#39;Malley JT&lt;/searchLink&gt;; Sanofi, Cambridge, MA, USA.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Patel+N%22&quot;&gt;Patel N&lt;/searchLink&gt;; Sanofi, Cambridge, MA, USA.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Graham+NMH%22&quot;&gt;Graham NMH&lt;/searchLink&gt;; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.&lt;br /&gt;&lt;searchLink fieldCode=&quot;AU&quot; term=&quot;%22Bansal+A%22&quot;&gt;Bansal A&lt;/searchLink&gt;; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%220004041%22&quot;&gt;The British journal of dermatology&lt;/searchLink&gt; [Br J Dermatol] 2021 May; Vol. 184 (5), pp. 857-870. &lt;i&gt;Date of Electronic Publication: &lt;/i&gt;2020 Oct 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov&#39;t
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: &lt;i&gt;Publisher: &lt;/i&gt;&lt;searchLink fieldCode=&quot;PB&quot; term=&quot;%22Oxford+University+Press%22&quot;&gt;Oxford University Press &lt;/searchLink&gt;&lt;i&gt;Country of Publication: &lt;/i&gt;England &lt;i&gt;NLM ID: &lt;/i&gt;0004041 &lt;i&gt;Publication Model: &lt;/i&gt;Print-Electronic &lt;i&gt;Cited Medium: &lt;/i&gt;Internet &lt;i&gt;ISSN: &lt;/i&gt;1365-2133 (Electronic) &lt;i&gt;Linking ISSN: &lt;/i&gt;&lt;searchLink fieldCode=&quot;IS&quot; term=&quot;%2200070963%22&quot;&gt;00070963 &lt;/searchLink&gt;&lt;i&gt;NLM ISO Abbreviation: &lt;/i&gt;Br J Dermatol &lt;i&gt;Subsets: &lt;/i&gt;MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32969489
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/bjd.19460
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 857
    Titles:
      – TitleFull: Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to &lt; 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cork MJ
      – PersonEntity:
          Name:
            NameFull: Thaçi D
      – PersonEntity:
          Name:
            NameFull: Eichenfield LF
      – PersonEntity:
          Name:
            NameFull: Arkwright PD
      – PersonEntity:
          Name:
            NameFull: Sun X
      – PersonEntity:
          Name:
            NameFull: Chen Z
      – PersonEntity:
          Name:
            NameFull: Akinlade B
      – PersonEntity:
          Name:
            NameFull: Boklage S
      – PersonEntity:
          Name:
            NameFull: Guillemin I
      – PersonEntity:
          Name:
            NameFull: Kosloski MP
      – PersonEntity:
          Name:
            NameFull: Kamal MA
      – PersonEntity:
          Name:
            NameFull: O'Malley JT
      – PersonEntity:
          Name:
            NameFull: Patel N
      – PersonEntity:
          Name:
            NameFull: Graham NMH
      – PersonEntity:
          Name:
            NameFull: Bansal A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2021 May
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1365-2133
          Numbering:
            – Type: volume
              Value: 184
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: The British journal of dermatology
              Type: main
ResultId 1